FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
|Articles|October 13, 2020
CooperVision releases MiSight 6-year data
6-year data on MiSight contact lenses
Advertisement
Paul Chamberlain, who serves as CooperVision’s director of research programs, myopia, spoke with Optometry Times® Editor in Chief Gretchyn Bailey about the company’s 6-year data on MiSight contact lenses. Chamberlain discussed clinical implications of the data and next steps for following children wearing the daily disposable myopia management contact lenses.
Advertisement
Related to this article
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Kevin Chan, OD, MS, FAAO, FBCLA, IACMM, stated in his Rapid Fire lecture that high myopes shouldn't be counted out of orthokeratology treatment.
Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.
Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
More than monitoring: Using AMD visits to promote healthy vision aging
2
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
3
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
4
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5